An interim analysis of a real-world study of adults with atopic dermatitis (AD) presented at AMCP Nexus 2019 revealed that dupilumab correlates with increased treatment satisfaction and a sharp decline in concomitant AD therapies, specifically systemic corticosteroids (SCS).
The drug is currently approved for patients with moderate-to-severe AD not being properly managed by topical treatments. This approval applies only to patients 12 years or older in the US and adults in Europe. This study assessed change in treatment (Tx) satisfaction and concomitant AD therapies following dupilumab initiation from the EaRly REal WorLd Patient EValuation for dupilumab in Atopic Dermatitis (RELIEVE-AD) study, a prospective, longitudinal patient survey conducted in the US.
This new research assessed change in treatment satisfaction and concomitant treatments after the initiation of dupilumab treatment. The data were obtained from the patients enrolled in a prospective, longitudinal patient survey in the US called the EaRly REal WorLd Patient EValuation for dupilumab in Atopic Dermatitis (RELIEVE-AD) study. Patients who were invited to participate were adults with AD who had been prescribed dupilumab and were enrolled in its patient support program in the US.
Participants were surveyed at baseline prior to being given dupilumab, and again at one, two, three, six, nine, and 12 months follow-up. Baseline treatment was defined as the use of prescription topicals (corticosteroids, calcineurin inhibitors), PDE4 inhibitor, systemic corticosteroids, systemic immunosuppressants, or phototherapy in the past 4 weeks. This interim 6-month analysis (data-cut: Dec 6, 2018) included patient reported satisfaction with current treatments for AD and use of simultaneous AD treatments before and after dupilumab treatment had begun.
A total of 674 of the 1,010 patients responding to the baseline survey reported initiating dupilumab. The response rates of eligible patients were 89.8%, 89.1%, 84.2%, and 74.4% at months one, two, three, and six, respectively. The demographic and clinical findings at months 3 and 6 were comparable to those of the full sample. Those who reported to be very/extremely satisfied with their existing AD treatments increased from 2.9% at baseline to 57.8% at month one and 70.9% at month six (both P < 0.001).
Those who used concomitant AD treatments from three or more drug categories saw a reduction from 13.1% at baseline to 1.7% at month one and 1.5% at month six (both P < 0.001), and use from two different categories reduced from 34.3% to 14.7% and 12.1% at months one and six, respectively (both P < 0.001). The observed trends for treatments with individual drug categories were similar, with those for SCS decreasing by 73.5% by month six. The proportion of those with no concomitant AD therapy increased from the baseline 12.8% to 39.6% at month one and 41.3% at month six (both P < 0.001).
“While this dataset is still maturing, in this interim-analysis of a real-world study of adults with AD, dupilumab introduction corresponded with increased Tx satisfaction and rapid decline in concomitant AD therapies, especially SCS,” the authors concluded. “These data support the evidence demonstrating effectiveness of dupilumab for adults with moderate-to-severe AD.”
This research was sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
Meeting Abstract: Kimball, A, Mallya U, et al. Dupilumab improves treatment satisfaction and reduces treatment burden in adults with atopic dermatitis: Results from EaRly REal WorLd Patient EValuation for dupilumab in Atopic Dermatitis (RELIEVE AD) study. Presented at: AMCP Nexus 2019; October 29 – Nov 1; National Harbor, MD.